Primary ipilimumab/nivolumab followed by adjuvant nivolumab in patients with locally advanced or oligometastatic melanoma: Update on outcome.

This article has no abstract
Epistemonikos ID: 3bc708fe06cc776a8e57b7409be8cbdcc270833e
First added on: Feb 15, 2025